CA2953884C - Mesenchymal stromal cells for treating sepsis - Google Patents

Mesenchymal stromal cells for treating sepsis Download PDF

Info

Publication number
CA2953884C
CA2953884C CA2953884A CA2953884A CA2953884C CA 2953884 C CA2953884 C CA 2953884C CA 2953884 A CA2953884 A CA 2953884A CA 2953884 A CA2953884 A CA 2953884A CA 2953884 C CA2953884 C CA 2953884C
Authority
CA
Canada
Prior art keywords
cells
mscs
composition
cell
sepsis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2953884A
Other languages
English (en)
French (fr)
Other versions
CA2953884A1 (en
Inventor
Wilfried Dalemans
Eleuterio Lombardo
Robert Dekker
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Takeda Pharmaceutical Co Ltd
Original Assignee
Tigenix SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tigenix SA filed Critical Tigenix SA
Publication of CA2953884A1 publication Critical patent/CA2953884A1/en
Application granted granted Critical
Publication of CA2953884C publication Critical patent/CA2953884C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021—Intradermal administration, e.g. through microneedle arrays or needleless injectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0031—Rectum, anus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Developmental Biology & Embryology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Virology (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Wood Science & Technology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Otolaryngology (AREA)
  • Genetics & Genomics (AREA)
  • Nutrition Science (AREA)
  • Gynecology & Obstetrics (AREA)
  • Microbiology (AREA)
  • Dispersion Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Neurosurgery (AREA)
  • Physiology (AREA)
  • Reproductive Health (AREA)
CA2953884A 2014-06-30 2015-06-30 Mesenchymal stromal cells for treating sepsis Active CA2953884C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP14175095 2014-06-30
EP14175095.0 2014-06-30
PCT/IB2015/054923 WO2016001846A1 (en) 2014-06-30 2015-06-30 Mesenchymal stromal cells for treating sepsis

Publications (2)

Publication Number Publication Date
CA2953884A1 CA2953884A1 (en) 2016-01-07
CA2953884C true CA2953884C (en) 2022-12-06

Family

ID=51033023

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2953884A Active CA2953884C (en) 2014-06-30 2015-06-30 Mesenchymal stromal cells for treating sepsis

Country Status (14)

Country Link
US (2) US20170151284A1 (enExample)
EP (1) EP3160481B1 (enExample)
JP (1) JP6722599B2 (enExample)
KR (1) KR102213527B1 (enExample)
CN (1) CN106573017B (enExample)
AU (1) AU2015283662B2 (enExample)
BR (1) BR112016030758B8 (enExample)
CA (1) CA2953884C (enExample)
IL (1) IL249814B (enExample)
MX (1) MX381544B (enExample)
NZ (1) NZ727950A (enExample)
RU (1) RU2715866C2 (enExample)
SG (1) SG11201610844PA (enExample)
WO (1) WO2016001846A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11518982B2 (en) * 2015-12-01 2022-12-06 Adiposeeds, Inc. Method for manufacturing mesenchymal cell line derived from vertebrate animal adipose tissue
US11701389B2 (en) * 2016-03-09 2023-07-18 Emory University Methods of preserving mesenchymal stem cells
GB201604304D0 (en) * 2016-03-14 2016-04-27 Tigenix S A U Adipose tissue-derived stromal stem cells for use in treating refractory complex perianal fistulas in crohn's disease
ES2927203T3 (es) 2017-02-28 2022-11-03 Univ De Lorraine Células madre mesenquimales derivadas de la gelatina de Wharton para el tratamiento de la sepsis
US11524000B2 (en) 2017-10-26 2022-12-13 Emory University Targeting Mcl-1 to enhance DNA replication stress sensitivity for cancer therapy
KR20250160527A (ko) * 2018-06-05 2025-11-13 메디포스트(주) 히알루론산과 줄기세포를 포함하는 연골손상 관련 질환 치료용 약학 조성물
EP3874029B1 (en) * 2018-10-29 2023-08-30 Ottawa Hospital Research Institute Genetically-engineered mesenchymal stem cells overexpressing aoah and uses thereof
EP4098267A4 (en) * 2020-01-30 2024-03-06 JCR Pharmaceuticals Co., Ltd. MEDICINAL COMPOSITION COMPRISING CELLS DERIVED FROM DENTAL PULP
US20240226173A1 (en) * 2021-05-13 2024-07-11 Primegen Us, Inc. Methods and compositions for treating liver disease
CN113398150A (zh) * 2021-06-18 2021-09-17 卡替(上海)生物技术有限公司 牙髓间充质干细胞在脓毒症治疗中的应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU673877B2 (en) 1992-12-02 1996-11-28 Shell Internationale Research Maatschappij B.V. Azoxycyanobenzene derivatives
US5578475A (en) 1993-07-12 1996-11-26 Life Technologies, Inc. Composition and methods for transfecting eukaryotic cells
US6051429A (en) 1995-06-07 2000-04-18 Life Technologies, Inc. Peptide-enhanced cationic lipid transfections
ATE285477T1 (de) 1995-06-07 2005-01-15 Inex Pharmaceutical Corp Herstellung von lipid-nukleinsäure partikeln duch ein hydrophobische lipid-nukleinsäuree komplexe zwischenprodukt und zur verwendung in der gentransfer
US5744335A (en) 1995-09-19 1998-04-28 Mirus Corporation Process of transfecting a cell with a polynucleotide mixed with an amphipathic compound and a DNA-binding protein
US5705308A (en) 1996-09-30 1998-01-06 Eastman Kodak Company Infrared-sensitive, negative-working diazonaphthoquinone imaging composition and element
US6777231B1 (en) 1999-03-10 2004-08-17 The Regents Of The University Of California Adipose-derived stem cells and lattices
WO2005093044A1 (en) * 2004-03-22 2005-10-06 Osiris Therapeutics, Inc. Mesenchymal stem cells and uses therefor
MX342474B (es) 2005-09-23 2016-09-30 Cellerix Sl Poblaciones celulares con actividad inmunoreguladora, método de aislamiento y usos.
GB0814249D0 (en) * 2008-08-04 2008-09-10 Cellerix Sa Uses of mesenchymal stem cells
CA2829586C (en) * 2011-03-11 2021-03-02 Children's Medical Center Corporation Methods and compositions relating to mesenchymal stem cell exosomes
JP2014016782A (ja) * 2012-07-09 2014-01-30 Toshiba Corp 情報処理装置およびプログラム
US20140134140A1 (en) * 2012-11-09 2014-05-15 Case Western Reserve University Mesenchymal stem cell compositions for the treatment of microbial infections

Also Published As

Publication number Publication date
WO2016001846A1 (en) 2016-01-07
CN106573017A (zh) 2017-04-19
RU2715866C2 (ru) 2020-03-03
KR20170021343A (ko) 2017-02-27
RU2016151738A3 (enExample) 2019-01-30
SG11201610844PA (en) 2017-01-27
BR112016030758B1 (pt) 2021-10-13
KR102213527B1 (ko) 2021-02-09
AU2015283662A1 (en) 2017-01-19
IL249814B (en) 2020-02-27
US20170151284A1 (en) 2017-06-01
EP3160481A1 (en) 2017-05-03
JP6722599B2 (ja) 2020-07-15
BR112016030758B8 (pt) 2022-10-25
CN106573017B (zh) 2021-06-11
JP2017520583A (ja) 2017-07-27
NZ727950A (en) 2022-07-01
MX381544B (es) 2025-03-12
CA2953884A1 (en) 2016-01-07
BR112016030758A2 (enExample) 2017-08-22
EP3160481B1 (en) 2020-09-09
MX2017000142A (es) 2017-07-28
AU2015283662B2 (en) 2020-09-24
IL249814A0 (en) 2017-03-30
RU2016151738A (ru) 2018-07-30
US20200376038A1 (en) 2020-12-03

Similar Documents

Publication Publication Date Title
US20200376038A1 (en) Mesenchymal stromal cells for treating sepsis
US20220088084A1 (en) Uses of mesenchymal stem cells
JP6764912B2 (ja) 免疫調節活性を有する細胞集団、その調製方法および使用
EP3260533B1 (en) Methods for treating radiation or chemical injury
EP3160480B1 (en) Mesenchymal stromal cells for treating rheumatoid arthritis
CN115197905B (zh) 活化血小板在制备促进间充质干细胞迁移产品中的应用
Delgado et al. Uses of mesenchymal stem cells
HK1224333B (en) Cell populations having immunoregulatory activity, methods for the preparation and uses thereof
HK1230927A1 (en) Uses of mesenchymal stem cells
AU2015268704A1 (en) Uses of mesenchymal stem cells

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20200601

EEER Examination request

Effective date: 20200601

EEER Examination request

Effective date: 20200601

EEER Examination request

Effective date: 20200601

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 10TH ANNIV.) - STANDARD

Year of fee payment: 10

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250521

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250523